Paper6366135
Influence of tumor estrogen and progesterone receptor levels on the response to tamoxifen and chemotherapy in primary breast cancer.
Fisher B and 9 others. J Clin Oncol, 1983. Cited by 255 papers, by iCite.
Cite this record
ConductScience Library. Influence of tumor estrogen and progesterone receptor levels on the response to tamoxifen and chemotherapy in primary breast cancer. Papers, record 6366135. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/6366135
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- Influence of tumor estrogen and progesterone receptor levels on the response to tamoxifen and chemotherapy in primary breast cancer.
- PubMed
- Publication types
- Clinical Trial, Comparative Study, Journal Article, Randomized Controlled Trial, Research Support, Non-U.S. Gov't, Research Support, U.S. Gov't, P.H.S.
- PubMed
Topics15
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Antineoplastic Combined Chemotherapy Protocols | Major topic |
| Breast Neoplasms | Major topic |
| Receptors, Estrogen | Major topic |
| Receptors, Progesterone | Major topic |
| Tamoxifen | Major topic |
| Age Factors | |
| Clinical Trials as Topic | |
| Female | |
| Fluorouracil | |
| Humans | |
| Lymph Nodes | |
| Melphalan | |
| Middle Aged | |
| Prognosis | |
| Statistics as Topic |
Source PubMed
Grants2
Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.
| Grant, as the record writes it | Agency | Country | NIH project | Stated by | Source |
|---|---|---|---|---|---|
| N01-CB-23876 | NCI NIH HHS | United States | N01CB023876 | PubMed and NIH | NIH RePORTER |
| R01-CA-12027 | NCI NIH HHS | United States | PubMed | PubMed |
Comments and corrections1
PubMed's comments and corrections, NLM's own indexing: retractions first, then expressions of concern, errata and updates, and comments last.
| Kind | PMID | Title | In Papers |
|---|---|---|---|
| Comment in | 18445835 | Evolution of knowledge related to breast cancer heterogeneity: a 25-year retrospective. | https://conductscience.org/library/papers/18445835 |
Source PubMed
Cited by56
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 255 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 39924532 | An assessment of breast cancer HER2, ER, and PR expressions based on mammography using deep learning with convolutional neural networks. | Sci Rep | 2025 | https://conductscience.org/library/papers/39924532 | PubMed |
| 37192893 | ROS Generative Black Phosphorus-Tamoxifen Nanosheets for Targeted Endocrine-Sonodynamic Synergistic Breast Cancer Therapy. | Int J Nanomedicine | 2023 | https://conductscience.org/library/papers/37192893 | PubMed |
| 37065867 | Targeting hormone-resistant breast cancer cells with docetaxel: a look inside the resistance. | Cancer Drug Resist | 2023 | https://conductscience.org/library/papers/37065867 | PubMed |
| 34625570 | A careful reassessment of anthracycline use in curable breast cancer. | NPJ Breast Cancer | 2021 | https://conductscience.org/library/papers/34625570 | PubMed |
| 33723286 | Pancancer survival analysis of cancer hallmark genes. | Sci Rep | 2021 | https://conductscience.org/library/papers/33723286 | PubMed |
| 33112838 | Serine synthesis influences tamoxifen response in ER+ human breast carcinoma. | Endocr Relat Cancer | 2021 | https://conductscience.org/library/papers/33112838 | PubMed |
| 32266132 | Sphingosine Kinase 1 in Breast Cancer-A New Molecular Marker and a Therapy Target. | Front Oncol | 2020 | https://conductscience.org/library/papers/32266132 | PubMed |
| 31359505 | Relationships of protein biomarkers of the urokinase plasminogen activator system with expression of their cognate genes in primary breast carcinomas. | J Clin Lab Anal | 2019 | https://conductscience.org/library/papers/31359505 | PubMed |
| 31073534 | Precision Medicine. | Annu Rev Stat Appl | 2019 | https://conductscience.org/library/papers/31073534 | PubMed |
| 29858579 | Macrodissection prior to closed system RT-qPCR is not necessary for estrogen receptor and HER2 concordance with IHC/FISH in breast cancer. | Lab Invest | 2018 | https://conductscience.org/library/papers/29858579 | PubMed |
| 29752560 | Anthracycline Use for Early Stage Breast Cancer in the Modern Era: a Review. | Curr Treat Options Oncol | 2018 | https://conductscience.org/library/papers/29752560 | PubMed |
| 28971320 | Expression of Genes for Methylxanthine Pathway-Associated Enzymes Accompanied by Sex Steroid Receptor Status Impacts Breast Carcinoma Progression. | Horm Cancer | 2017 | https://conductscience.org/library/papers/28971320 | PubMed |
| 27619909 | Prognostic values of negative estrogen or progesterone receptor expression in patients with luminal B HER2-negative breast cancer. | World J Surg Oncol | 2016 | https://conductscience.org/library/papers/27619909 | PubMed |
| 27141007 | Quantifying Treatment Benefit in Molecular Subgroups to Assess a Predictive Biomarker. | Clin Cancer Res | 2016 | https://conductscience.org/library/papers/27141007 | PubMed |
| 26858530 | Targeted therapies with companion diagnostics in the management of breast cancer: current perspectives. | Pharmgenomics Pers Med | 2016 | https://conductscience.org/library/papers/26858530 | PubMed |
| 26657878 | Immunohistochemical Performance of Estrogen and Progesterone Receptor Antibodies on the Dako Omnis Staining Platform: Evaluation in Multicenter Studies. | Appl Immunohistochem Mol Morphol | 2017 | https://conductscience.org/library/papers/26657878 | PubMed |
| 25217578 | Biomarker testing for breast, lung, and gastroesophageal cancers at NCI designated cancer centers. | J Natl Cancer Inst | 2014 | https://conductscience.org/library/papers/25217578 | PubMed |
| 24199171 | In situ Protein Detection for Companion Diagnostics. | Front Oncol | 2013 | https://conductscience.org/library/papers/24199171 | PubMed |
| 23645940 | Estimating Optimal Treatment Regimes from a Classification Perspective. | Stat | 2012 | https://conductscience.org/library/papers/23645940 | PubMed |
| 23568563 | Protein tyrosine phosphatase 4A2 expression predicts overall and disease-free survival of human breast cancer and is associated with estrogen and progestin receptor status. | Horm Cancer | 2013 | https://conductscience.org/library/papers/23568563 | PubMed |
Genes2
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
| Gene | NCBI Gene ID | Linked by | In Genes | Source |
|---|---|---|---|---|
| ESR1 | 2099 | PubTator's text mining | https://conductscience.org/library/genes/2099 | NCBI Gene |
| PGR | 5241 | PubTator's text mining | https://conductscience.org/library/genes/5241 | NCBI Gene |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Trials
- References
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/6366135
GET https://conductscience.org/api/papers/v1/6366135/cited_by?page=2